 I'm a molecular biologist and I'm now master of Trinity College Cambridge. Probably the most important contribution has been the development of technologies for making therapeutic antibodies. This has led to a revolution in the pharmaceutical industry and antibodies are now major drugs. What drives me? Science is fun. It's fun to make discoveries and it's fun to work in a team with other scientists. It's a primordial thing. Imagine a tribe going off into the jungle to hunt and it's all in a good cause finding new medicines. One factor that's been crucial for my development as a scientist has been the freedom to pursue my own ideas. My funding came from Trinity College and from the Medical Research Council Laboratory of Molecular Biology and they've always given me complete freedom to do what I want to do. As importantly, I've been in the right place at the right time with the right skills. The MRC Laboratory of Molecular Biology is a great institution and attracted great scientists such as Cesar Milstein and Fred Sanger. Shortly after I joined the laboratory as a student, Cesar Milstein discovered how to make monoclonal antibodies and Fred Sanger how to read the sequence of DNA. The atmosphere was exhilarating and it inspired us to think big. I thought about creating a new world of engineered proteins and in due course found a niche creating therapeutic antibodies. The science alone wasn't sufficient to turn these inventions into medicines. I had to get involved with writing patterns and more generally with the commercial world. In 1990 I even had to set up a company Cambridge Antibody Technology. I went from being a scientist to an inventor to an entrepreneur. My next objective is to solve a problem with antibodies. They're quite large molecules and don't easily get from the blood into the tissues and into tumours. To overcome this we're developing bicyclic peptides, a small antibody mimics. Cable of quickly penetrating tissues and killing tumours. I've set up another company, Bicycle Therapeutics, which is based at the Baberham Science Campus just outside Cambridge. I have several personal connections with Aarhus University. I knew the late Professor Brian Clark and I know both Peter Christensen and Luis Alvarez Velina, who were post-doctoral workers in my laboratory in Cambridge. We might even work together again. There's certainly enough common interest and background. Greg Winter is a pioneer in the field of therapeutic monoclonal antibodies and the inventor of breakthrough techniques for making them for medical treatment. Today these techniques are used in more than two-thirds of the antibody products currently on the market, including the first human antibody, which was approved by the US FDA and sold under the name Humira. Greg Winter's outstanding work with human antibodies has laid the foundation for many modern medical treatments and he is one of the few scientists who can truly say that his contribution has been to the benefit of society. Greg Winter is also an entrepreneur having founded several successful biotech companies. Greg Winter has an impressive scientific curriculum and has through his outstanding achievements won several prestigious international prizes. He is a fellow of the Royal Society and fellow of the Academy of Medical Sciences. In 2004 Greg Winter was knighted for his service to science and in 2012 he became the master of Trinity College in Cambridge. Greg Winter has a long tradition for working with Orhus University and has visited our university several times. Dear Sir Gregory Winter, on this background it is my greatest privilege and pleasure to confer upon you the degree Doctor Scientarium Honoros Causa at Orhus University.